Aside from testosterone replacement to younger men with proven testosterone deficiency, evidence of benefit from hormonal or pharmacological therapy to increase sexual desire is minimal.
Recent studies have shown that the local delivery of the main precursor hormone of testosterone and estrogen, dehydroepiandrosterone (DHEA) effectively treats dyspareunia and dryness from VVA and does not increase serum levels of estrogen and testosterone.
How to manage PVD is an extremely common question. PVD affects 12 -15 % women most of whom are relatively young. The common co-morbidity of PVD strongly supports a chronic pain approach.
Although men with repeatedly low serum testosterone levels typically have low sexual desire, no such link has been identified in women.
Recent Comments